OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company that aims to establish industry-leading positions in large and rapidly growing medical markets by leveraging its discovery, development, and commercialization expertise and its novel and proprietary technologies. The company intends to leverage its global commercialization expertise to pursue acquisitions of commercial businesses that will both drive growth and provide geographically diverse sales and distribution opportunities. OPKO has and may continue to make investments in other early stage companies that the company perceives to have valuable proprietary technology and significant potential to create value for OPKO as a shareholder.

Patents 478show all

  • 67
    A61K - Preparations for medical, dental, or toilet purposes
  • 61
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 37
    B01L - Chemical or physical laboratory apparatus for general use
  • 27
    C07D - Heterocyclic compounds
  • 16
    G16B - Bioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology
  • 16
    G16H - Healthcare informatics, i.e. information and communication technology [ict] specially adapted for the handling or processing of medical or healthcare data
  • 15
    A61B - Diagnosis
  • 11
    C12Y - Enzymes
  • 10
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 9
    C07H - Sugars

Clinical Trials 51show all

17Phase 214Phase 18N/A8Phase 33Other

SEC Filings show all


198
8-K

66
10-Q

20
10-K

3
D

1
S-1

Contact Information

4400 Biscayne Blvd.
Miami, FL 33137
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$206,000,000501-10002013-02-15Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2009-06-03$31,000,000Post Ipo Equity
2013-02-15$175,000,000Post Ipo Debt

SEC Form D Funding Events

DateOfferedSoldType
2013-02-15$175,000,000$175,000,000Equity, Debt
2009-06-03$31,000,000$31,000,000Equity
2007-04-16Unknown Unknown Other (Paper Filing)

Key Executives

  • Phillip Frost
    Executive Officer, Director
  • Jane H. Hsiao
    Executive Officer, Director
  • Steven D. Rubin
    Executive Officer, Director
  • Rao Uppaluri
    Executive Officer
  • Naveed K Shams
    Executive Officer
  • Robert A. Baron
    Director
  • Thomas E. Beier
    Director
  • Pascal J. Goldschmidt
    Director
  • Richard A. Lerner
    Director
  • John A. Paganelli
    Director
  • Richard C. Pfenniger, Jr.
    Director
  • Alice Lin-Tsing Yu
    Director
  • Juan F. Rodriguez
    Executive Officer
  • Dmitry Kolosov
    Director